Clinical Trials Logo
  1. Home
  2. Viral Infection
  3. NCT04519307
  4. Details
NCT04519307 Clinical Trial

Evaluation of Newborns Presenting With Suspected COVID 19

Viral Infection Clinical Trial

Official title:
Evaluation of Newborns Presenting With Suspected COVID 19: A Single Center Experience

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT04519307
Other study ID # 2020/251
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date March 1, 2020
Est. completion date August 31, 2020

Study information
Verified date August 2020
Source Dr. Behcet Uz Children's Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study evaluates the newborns who had respiratory symptoms at the neonatal intensive care admission

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 72
Est. completion date August 31, 2020
Est. primary completion date August 1, 2020
Accepts healthy volunteers No
Gender All
Age group N/A to 1 Month
Eligibility Inclusion Criteria:

- All newborns who had respiratory symptoms at the NICU admission

Exclusion Criteria:

- Congenital abnormalities

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Turkey Izmir Dr. Behcet Uz Training and Research Hospital Izmir

Sponsors (1)
Lead Sponsor Collaborator
Dr. Behcet Uz Children's Hospital

Country where clinical trial is conducted

Turkey, 

Outcome
Type Measure Description Time frame Safety issue
Primary General Characteristics of the infants with respiratory infection at the NICU admission Demographical characteristics will be recorded 5 months
See also
  Status Clinical Trial Phase
Recruiting NCT05568953 - An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity Phase 2
Not yet recruiting NCT05953233 - School Inner City Air Study N/A
Not yet recruiting NCT05902702 - Isotonic Saline for Children With Bronchiolitis N/A
Completed NCT01570283 - ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus Phase 1/Phase 2
Not yet recruiting NCT01159470 - The Rate of C-reactive Protein (CRP) Increase as a Marker for Bacterial Infections in Children N/A
Recruiting NCT02532452 - Third Party Viral Specific T-cells (VSTs) Phase 2
Recruiting NCT05246098 - REVIVe: Frailty, Rehabilitation, and Outcomes in Critically Ill Adult and Pediatric Survivors of COVID-19 or ARI
Recruiting NCT05603650 - Effects of Mouthrinses on the Microbiome of the Oral Cavity and GI Tract N/A
Completed NCT04525456 - Immune Responses With Reduxium N/A
Completed NCT04643678 - Anakinra in the Management of COVID-19 Infection Phase 2/Phase 3
Completed NCT03189537 - Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections Phase 3
Completed NCT04267809 - Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection Phase 2
Completed NCT00341081 - Validation of Self-Reported Needle Sharing Among Injection Drug Users N/A
Recruiting NCT04088916 - Proviral DNA as a Target for HIV-1 Resistance Analysis
Terminated NCT04401410 - Anti-SARS Cov-2 T Cell Infusions for COVID 19 Phase 1
Terminated NCT00952185 - Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers N/A
Recruiting NCT06149494 - RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection Phase 2
Active, not recruiting NCT04254991 - A Controlled, Blinded Study to Validate the Diagnostic Accuracy and Assess the Clinical Utility of a Host-response Based Diagnostic Tool for Distinguishing Between Bacterial and Viral Etiologies in Pediatric Patients Presenting to the ED With Suspicion of Acute Infection
Completed NCT05897801 - Distinguishing Bacterial and Viral Infections by MeMed BV® Test to Limit Gut Colonization by MDRO
Terminated NCT02696291 - Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects Phase 1